Cargando…

Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance

The transcription factors and proto-oncogenes STAT3 and STAT5 are highly activated in hematological malignancies and represent promising therapeutic targets. Whereas the importance of STAT5 as tumor promoter is beyond doubt, the role of STAT3 in hematological cancers is less well understood. Both, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Putz, Eva Maria, Hoelzl, Maria Agnes, Baeck, Julia, Bago-Horvath, Zsuzsanna, Schuster, Christian, Reichholf, Brian, Kern, Daniela, Aberger, Fritz, Sexl, Veronika, Hoelbl-Kovacic, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980609/
https://www.ncbi.nlm.nih.gov/pubmed/24473086
http://dx.doi.org/10.3390/cancers6010193
_version_ 1782479555881074688
author Putz, Eva Maria
Hoelzl, Maria Agnes
Baeck, Julia
Bago-Horvath, Zsuzsanna
Schuster, Christian
Reichholf, Brian
Kern, Daniela
Aberger, Fritz
Sexl, Veronika
Hoelbl-Kovacic, Andrea
author_facet Putz, Eva Maria
Hoelzl, Maria Agnes
Baeck, Julia
Bago-Horvath, Zsuzsanna
Schuster, Christian
Reichholf, Brian
Kern, Daniela
Aberger, Fritz
Sexl, Veronika
Hoelbl-Kovacic, Andrea
author_sort Putz, Eva Maria
collection PubMed
description The transcription factors and proto-oncogenes STAT3 and STAT5 are highly activated in hematological malignancies and represent promising therapeutic targets. Whereas the importance of STAT5 as tumor promoter is beyond doubt, the role of STAT3 in hematological cancers is less well understood. Both, enforced as well as attenuated expression of STAT3 were reported in hematopoietic malignancies. Recent evidence implicates STAT3 as key player for tumor immune surveillance as it both mediates the production of and response to inflammatory cytokines. Here we investigated the effects of STAT3 deletion in a BCR/ABL-induced lymphoma model, which is tightly controlled by natural killer (NK) cells in vivo. Upon STAT3 deletion tumor growth is significantly enhanced when compared to STAT3-expressing controls. The increased tumor size upon loss of STAT3 was accompanied by reduced NK cell infiltration and decreased levels of the cytokine IFN-γ and the chemokine RANTES. Upon transplantation into NK cell-deficient mice differences in lymphoma size were abolished indicating that STAT3 expression in the tumor cells controls NK cell-dependent tumor surveillance. Our findings indicate that STAT3 inhibition in lymphoma patients will impair NK cell-mediated tumor surveillance, which needs to be taken into account when testing STAT3 inhibitors in preclinical or clinical trials.
format Online
Article
Text
id pubmed-3980609
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-39806092014-04-09 Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance Putz, Eva Maria Hoelzl, Maria Agnes Baeck, Julia Bago-Horvath, Zsuzsanna Schuster, Christian Reichholf, Brian Kern, Daniela Aberger, Fritz Sexl, Veronika Hoelbl-Kovacic, Andrea Cancers (Basel) Article The transcription factors and proto-oncogenes STAT3 and STAT5 are highly activated in hematological malignancies and represent promising therapeutic targets. Whereas the importance of STAT5 as tumor promoter is beyond doubt, the role of STAT3 in hematological cancers is less well understood. Both, enforced as well as attenuated expression of STAT3 were reported in hematopoietic malignancies. Recent evidence implicates STAT3 as key player for tumor immune surveillance as it both mediates the production of and response to inflammatory cytokines. Here we investigated the effects of STAT3 deletion in a BCR/ABL-induced lymphoma model, which is tightly controlled by natural killer (NK) cells in vivo. Upon STAT3 deletion tumor growth is significantly enhanced when compared to STAT3-expressing controls. The increased tumor size upon loss of STAT3 was accompanied by reduced NK cell infiltration and decreased levels of the cytokine IFN-γ and the chemokine RANTES. Upon transplantation into NK cell-deficient mice differences in lymphoma size were abolished indicating that STAT3 expression in the tumor cells controls NK cell-dependent tumor surveillance. Our findings indicate that STAT3 inhibition in lymphoma patients will impair NK cell-mediated tumor surveillance, which needs to be taken into account when testing STAT3 inhibitors in preclinical or clinical trials. MDPI 2014-01-27 /pmc/articles/PMC3980609/ /pubmed/24473086 http://dx.doi.org/10.3390/cancers6010193 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Putz, Eva Maria
Hoelzl, Maria Agnes
Baeck, Julia
Bago-Horvath, Zsuzsanna
Schuster, Christian
Reichholf, Brian
Kern, Daniela
Aberger, Fritz
Sexl, Veronika
Hoelbl-Kovacic, Andrea
Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
title Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
title_full Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
title_fullStr Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
title_full_unstemmed Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
title_short Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance
title_sort loss of stat3 in lymphoma relaxes nk cell-mediated tumor surveillance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980609/
https://www.ncbi.nlm.nih.gov/pubmed/24473086
http://dx.doi.org/10.3390/cancers6010193
work_keys_str_mv AT putzevamaria lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT hoelzlmariaagnes lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT baeckjulia lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT bagohorvathzsuzsanna lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT schusterchristian lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT reichholfbrian lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT kerndaniela lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT abergerfritz lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT sexlveronika lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance
AT hoelblkovacicandrea lossofstat3inlymphomarelaxesnkcellmediatedtumorsurveillance